Prior to joining King’s College London and founding the Commercialisation Institute, Mike spent 33 years in the global and US pharmaceutical and UK medtech industries holding senior commercial operations, product development and corporate management roles. He has led the commercial development of three antivirals, zidovudine (Wellcome), valaciclovir (GlaxoSmithKline) and tenofovir df (Gilead Sciences), each achieving blockbuster status (turnover >£1bn p.a.). Mike was subsequently CEO of Molecular Skincare in the UK which he sold to York Pharma; he joined its board as commercial director, raising £50m in funding and completing three corporate acquisitions. Mike has held various executive and non-executive board director roles in private and public companies.